Arcturus Therapeutics Holdings (ARCT) Cash & Equivalents (2018 - 2026)

Arcturus Therapeutics Holdings' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $211.4 million for Q1 2026.

• Quarterly Cash & Equivalents fell 2.57% year-over-year to $211.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $211.4 million (down 2.57% YoY) and the FY2025 annual result came in at $230.9 million, down 21.44% from the prior year.
• Cash & Equivalents was $211.4 million for Q1 2026 at Arcturus Therapeutics Holdings, down from $230.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $391.9 million in Q4 2022 and bottomed at $180.4 million in Q3 2025.
• A 5-year average of $270.8 million and a median of $283.5 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 42.57% — and 2023, when it surged 31.24%.
• Arcturus Therapeutics Holdings' Cash & Equivalents stood at $391.9 million in 2022, then retreated by 25.49% to $292.0 million in 2023, then climbed by 0.65% to $293.9 million in 2024, then decreased by 21.44% to $230.9 million in 2025, then retreated by 8.46% to $211.4 million in 2026.
• Business Quant data shows ARCT's Cash & Equivalents at $211.4 million in Q1 2026, $230.9 million in Q4 2025, and $180.4 million in Q3 2025.